Nwam LLC Takes $247,000 Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Nwam LLC acquired a new stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the second quarter, Holdings Channel.com reports. The firm acquired 3,035 shares of the company’s stock, valued at approximately $247,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. General Electric Co. acquired a new stake in shares of GE HealthCare Technologies in the second quarter worth approximately $5,002,865,000. Bank of New York Mellon Corp acquired a new stake in shares of GE HealthCare Technologies in the second quarter worth approximately $330,208,000. Pzena Investment Management LLC acquired a new stake in shares of GE HealthCare Technologies in the second quarter worth approximately $209,044,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of GE HealthCare Technologies in the second quarter worth approximately $165,377,000. Finally, Swiss National Bank acquired a new stake in shares of GE HealthCare Technologies in the second quarter worth approximately $120,055,000. 79.18% of the stock is currently owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Performance

Shares of GE HealthCare Technologies stock opened at $73.00 on Friday. GE HealthCare Technologies Inc. has a 52 week low of $53.00 and a 52 week high of $87.83. The business’s fifty day simple moving average is $67.31 and its 200-day simple moving average is $73.31. The firm has a market cap of $33.23 billion and a PE ratio of 21.73. The company has a quick ratio of 0.97, a current ratio of 1.25 and a debt-to-equity ratio of 1.44.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings results on Tuesday, October 31st. The company reported $0.99 EPS for the quarter, beating the consensus estimate of $0.89 by $0.10. GE HealthCare Technologies had a return on equity of 24.46% and a net margin of 8.91%. The business had revenue of $4.82 billion for the quarter, compared to analyst estimates of $4.80 billion. During the same quarter in the prior year, the company posted $0.87 EPS. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Equities analysts forecast that GE HealthCare Technologies Inc. will post 3.81 earnings per share for the current year.

GE HealthCare Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 20th were paid a $0.03 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.16%. The ex-dividend date of this dividend was Thursday, October 19th. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.57%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GEHC. Bank of America began coverage on GE HealthCare Technologies in a research note on Monday, July 31st. They issued a “neutral” rating and a $82.00 price target on the stock. Citigroup assumed coverage on GE HealthCare Technologies in a research note on Tuesday, September 19th. They issued a “buy” rating and a $82.00 price target on the stock. Argus assumed coverage on GE HealthCare Technologies in a research note on Friday, August 25th. They set a “buy” rating and a $80.00 price objective on the stock. Finally, Wells Fargo & Company assumed coverage on GE HealthCare Technologies in a research note on Wednesday, August 16th. They set an “overweight” rating and a $90.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.44.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally.